Use of the “clot-busting” drug tissue plasminogen activator (tPA) to treat patients with strokes caused by a blockage of blood flow nearly doubled between 2003 and 2011. A research team reports both an overall increase in the use of tPA to dissolve clots blocking arteries supplying the brain and administration of the potentially life-saving drug to a more diverse group of patients.